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Araya RE, Gomez Castro MF, Carasi P, McCarville JL, Jury
J, Mowat AM, Verdu EF, Chirdo FG. Mechanisms of innate
immune activation by gluten peptide p31-43 in mice. Am J Physiol
Gastrointest Liver Physiol 311: G40–G49, 2016. First published May
5, 2016; doi:10.1152/ajpgi.00435.2015.—Celiac disease (CD) is an
immune-mediated enteropathy triggered by gluten in genetically sus-
ceptible individuals. Innate immunity contributes to the pathogenesis
of CD, but the mechanisms remain poorly understood. Although
previous in vitro work suggests that gliadin peptide p31-43 acts as an
innate immune trigger, the underlying pathways are unclear and have
not been explored in vivo. Here we show that intraluminal delivery of
p31-43 induces morphological changes in the small intestinal mucosa
of normal mice consistent with those seen in CD, including increased
cell death and expression of inflammatory mediators. The effects of
p31-43 were dependent on MyD88 and type I IFNs, but not Toll-like
receptor 4 (TLR4), and were enhanced by coadministration of the
TLR3 agonist polyinosinic:polycytidylic acid. Together, these results
indicate that gliadin peptide p31-43 activates the innate immune
pathways in vivo, such as IFN-dependent inflammation, relevant to
CD. Our findings also suggest a common mechanism for the potential
interaction between dietary gluten and viral infections in the patho-
genesis of CD.
celiac disease; innate immunity; p31-43; polyinosinic:polycytidylic
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CELIAC DISEASE (CD) is a multifactorial disorder triggered by the
ingestion of gluten in susceptible individuals who carry the
HLA-DQ2 and/or HLA-DQ8 predisposing alleles. Both innate
and adaptive immune mechanisms are involved in the patho-
genesis of CD. Whereas the adaptive immune response has
been well studied, less is known about innate mechanisms and
their triggers (1). Some gluten-derived peptides could initiate
this process, but there is not enough in vivo experimental
evidence to confirm this hypothesis. The study of whether and
how innate immune mechanisms are induced by gluten pep-
tides is relevant to CD pathophysiology.
Several nonimmunogenic gluten peptides that stimulate in-
nate immune responses (termed toxic peptides) but not the
adaptive immune response have been proposed. Studies have
shown that a mix of gluten peptides or pepsin-trypsin-digested
gliadin (PT-gliadin) can activate dendritic cells (26) and pe-
ripheral blood mononuclear cells (16) in vitro. However, the
peptides responsible have not been identified. The most studied
toxic peptide is the derived a-gliadin p31-43 (LGQQQPFP-
PQQPY) that is part of the longer peptide p31-55 (LGQQQP-
FPPQQPYPQPQPFPSQQPY) and is resistant to digestive en-
zymes in the gut (19). Increased IL-15 production and entero-
cyte apoptosis were reported in duodenal biopsies of patients
with CD incubated with p31-43 (18). p31-43 was also shown to
interact with epidermal growth factor receptor (EGFR) (5) and
with the IL-15/IL-15R complex (6, 24) to affect proliferative
activity in intestinal biopsies, influence human fibroblasts (23),
and induce oxidative stress and endosome maturation in en-
terocytes (17). In murine tissues, p31-43 induced proinflam-
matory cytokines by macrophages (34). Altogether, these stud-
ies suggest a role for p31-43 in the stimulation of innate
immune mechanisms in CD. However, the underlying path-
ways and in vivo relevance remain unclear.
Type I IFNs are thought to play a role in CD pathogenesis,
as there is increased expression of IFN-a in duodenal mucosa
from patients with CD (22) and blockade of IFN-a inhibits
gliadin-induced IFN-g expression in ex vivo experiments (28).
Furthermore, epidemiological studies suggest that enteric viral
infections such as rotavirus might trigger inflammatory or
functional gastrointestinal disease (20, 35). The aim of this
study was to determine whether p31-43 elicits innate immune
activation in murine small intestine in vivo and to investigate
potential underlying pathways. We also analyzed the effect of
combined intraluminal administration of p31-43 and polyinos-
inic:polycytidylic acid (poly I:C), which mimics a viral infec-
tion, a proposed trigger of CD.
MATERIALS AND METHODS
Mice. Eight-week-old male C57BL/6J mice were purchased from
the Animal Care Facility of the Facultad de Ciencias Exactas y
Naturales of the Universidad de Buenos Aires. Eight-week-old male
MyD88 KO [B6.129P2(SJL)-Myd88tm1.1Defr/J] mice were pur-
chased from the Jackson Laboratory. IFNaR knockout (KO) mice
(IFNabR2/2, IFNaR2/2) on C57BL/6 background were kindly pro-
vided by M. Albert (Institute Pasteur, Paris, France). Eight-week-old
male C3H-HeJ mice were kindly provided by Dr. Martin Rumbo from
Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-
CONICET, Buenos Aires, Argentina). Mice were housed in a specific
pathogen-free condition and fed ad libitum with balanced food and
autoclaved water. They were maintained on a 12-h:12-h light/dark
cycle and acclimatized to the surrounding conditions for 1 wk before
the experimental procedures. All the studies were performed in
accordance with international protocols for laboratory animal care
(Canadian Council on Animal Care). Experiments were conducted
with approval from the Institutional Animal Care and Use Committee
of the Facultad de Ciencias Exactas, Universidad Nacional de La
Plata.
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Intraluminal administration of peptides and poly I:C. p31-43 pep-
tide (LGQQQPFPPQQPY, Biomatik), nonrelated peptide (NRP) (LD-
PLIRGLLARPACALQV, Think Peptides), poly I:C (Sigma Aldrich),
a combination of p31-43 peptide and poly I:C, or PBS were admin-
istered intraluminally during intestinal microsurgery as previously
described (3). Briefly, mice were anaesthetized with 80 mg/kg ket-
amine and 10 mg/kg xylazine. Once asleep, 100 ml of 100 mg/ml
peptide solution in PBS, 30 mg/g poly I:C solution, or a combination
of p31-43 and poly I:C were injected into the small intestinal lumen,
2 cm below the pylorus, to avoid degradation by pancreatic enzymes.
Control mice received PBS. After surgery, fluid replacement was
administered, and mice were monitored until recovery. C57BL/6 mice
were killed 2–72 h posttreatment, whereas C3H-HeJ, IFNaR KO, and
MyD88 KO mice were killed 12 h posttreatment.
To compare the effects of p31-43, poly I:C, and p31-43 1 poly I:C
in C57BL/6 mice, histological evaluation was performed at 72 h
posttreatment. This time point was chosen based on the previous
finding indicating significant differences between treatments at this
time.
Histological evaluation. Sections of proximal small intestine of
treated mice were fixed in 10% formalin, embedded in paraffin, and
stained with hematoxylin and eosin for histological evaluation using a
Nikon Eclipse Ti fluorescence microscope with X-Cites Series 120 Q
light source. Images were taken with Nikon Digital Sight DS Ri1
camera using Nis-Elements software, and measurements were per-
formed using Image J software.
Two sections of the proximal small intestine were scored for
inflammation in a blinded fashion, with at least 30 villus-to-crypt
(V/C) ratios assessed in each mouse. Intraepithelial lymphocytes
(IELs) per 30 enterocytes in 10 randomly chosen villus tips were
counted according to previously described methods and expressed as
IELs/100 enterocytes (7). Histological scores were obtained following
the Park-Chiu criteria (27): 0, normal mucosa; 1, subepithelial space
at villus tips; 2, extension of subepithelial space with moderate lifting;
3, massive lifting down sides of villi, some denuded tips; 4, denuded
villi, dilated capillaries; 5, disintegration of lamina propria; 6, crypt
layer injury; 7, transmucosal infarction; 8, transmural infarction.
Real-time PCR. Small intestinal samples from C57BL/6 mice were
stored in RNALater at 280°C until use. Tissues were disrupted, and
RNA extraction was performed using RNeasy Mini Kit (Qiagen).
cDNA synthesis was performed from isolated RNA samples (2–5 mg),
using iScript Reverse Transcription Supermix (Bio-Rad). Real-time
PCR was performed with SsoFastEvaGreen Supermix (Bio-Rad)
using appropriate forward and reverse primers and the iQ5 thermo-
cycler with fluorescence detection (Bio-Rad). Reactions were run in
triplicate. The real-time PCR (qPCR) protocol was as follows: cycle
1 (13) 95°C for 10 min; cycle 2 (403) 60°C for 1 min and 95° for
15 s. Primers were synthesized as described previously (9) (Table 1).
The geometric mean of housekeeping gene HPRT was used as an
internal control to normalize the variability in expression levels. All
results were expressed as fold increase of each treatment vs. the mean
of PBS treatment in every time point (2 2DDCt method).
Isolation of epithelial cells and flow cytometric analysis. Sections
of proximal small intestine (10 cm) of PBS- and p31-43-treated
C57BL/6 mice were collected into cold calcium and magnesium-free
HBSS (Gibco). Tissue sections were then incubated in HBSS con-
taining 2% vol/vol FBS (Gibco) and 0.1 mM DTT (Sigma) at 4°C for
10 min before being incubated for 15 min at 37°C in HBSS with 0.5
mM EDTA (Sigma) with shaking. The cell suspensions were then
filtered through an 80-mm filter mesh (BD Biosciences) before use.
One million cells were used for flow cytometry analysis, and the
remaining cells were stored in RNALater (Ambion) for real-time PCR
analysis of Bax and Bcl2 mRNA expression as described above. For
flow cytometric analysis, cells were washed twice with annexin V
binding buffer and incubated for 30 min at room temperature using
annexin V-FITC (Immunotools). One minute before cell acquisition
propidium iodide (5 mg/tube) was added. Cells were analyzed in a BD
FACSCalibur flow cytometer (BD Bioscience), and data were pro-
cessed using CELLQest (BD Bioscience) software.
Confocal microscopy. Small intestinal sections were deparaffinized
and treated with Antigen Retrieval AR-10 Solution (BioGenex). After
the sections were blocked with 2% goat serum, a primary antibody
was added for 1 h. Anti-Ki-67 antibody (Novus Biologicals) was
added at 4°C, and Alexa488 goat anti-rabbit antibody (Molecular
Probes) was added at 10 mg/ml for 1 h. Anti-cleaved caspase-3
antibody conjugated to FITC (Cell Signaling) was added for 1 h at RT.
Nuclei were stained with propidium iodide at 1 mg/ml for 15 min.
Images were obtained and analyzed in a TCS SP5 Confocal Micro-
scope combined with Leica LAS AF software.
TUNEL reaction. Cell death was quantified using the In Situ Cell
Death Detection Kit (Roche). Paraffin-embedded small intestinal
tissue sections were dewaxed, rehydrated, and treated with Proteinase
K for permeabilization. TUNEL reaction mixture was then added, and
samples were analyzed by confocal microscopy. Images were taken
from a confocal microscope Olympus FV1000 using a 320 NA 0.75
objective and a zoom of 32. A 473-nm solid-state laser was used to
detect apoptotic cells, whereas a 405-nm state laser was used to
identify nuclei stained with DAPI. Images were analyzed with ImageJ
software.
Statistical analysis. Statistical analysis was performed with Graph-
Pad Prism software. When two groups were compared, an unpaired
t-test was used. When more than two groups were compared, a
one-way ANOVA test was used; P, 0.05 was considered significant.
Data are displayed as means 6 SE.
RESULTS
Intraluminal p31-43 peptide induces pathological changes
in the murine small intestine. We used a previously developed
technique to deliver molecules of interest intraluminally (3)
and tested the capacity of p31-43 to induce morphological
changes in small intestinal mucosa. At 12 h post p31-43
administration, we observed shortening and widening of villi,
increased cell infiltration in the lamina propria, and edema.
Administration of PBS or NRP did not cause intestinal damage
(Fig. 1A). At this time point, we also observed reduction in V/C
ratios, increased IEL counts, and higher histological scores in
mice treated with p31-43 compared with PBS and NRP (Fig.
1B). At 72 h, mice treated with p31-43 exhibited persistent
edema and cellular infiltration in the lamina propria (Fig. 1A),
reduced V/C ratios, increased number of IELs, and a higher
histological score compared with PBS- and NRP-treated mice
(Fig. 1B). Although the surgical procedure itself altered intes-
tinal histology transiently (3), PBS- and NRP-treated mice
(controls) experienced faster recovery than p31-43-treated
mice (Fig. 1B). We also evaluated the proliferative activity in
Table 1. Primers used for quantitative PCR
Gene Forward Reverse
HPRT CAATGCAAACTTTGCTTTCC CAAATCCAACAAAGTCTGGC
IFNb AATGGAAAGATCAACCTCAC AAGGCAGTGTAACTCTTCTG
CXCL10 ATAGGGAAGCTTGAAATCATCC TTCATCGTGGCAATGATCTC
CXCR3 TGTAGTTGGGCTAGCTCGAACTT ACCTGGATATATGCTGAGCTGTCA
TNFa CTCCCTCTCATCAGTTCTATGG TTGAGAAGATGATCTGAGTGTG
IL-15 CATCCATCTCGTGCTACTTGTGTT CATCTATCCAGTTGGCCTCTGTTT
MCP1 CTACAAGAGGATCACCAGCAG TTCTGATCTCATTTGGTTCCG
CXCL2 AAGATACTGAACAAAGGCAAGG TTCTTTCTCTTTGGTTCTTCCG
IL-1b CGTTCCCATTAGACAACTGC CTCATGGAGAATATCACTTGTTGG
IL-18 GATCAAAGTGCCAGTGAACC GATCTTGTTCTTACAGGAGAGG
IL-6 CATGTTCTCTGGGAAATCGT TATATCCAGTTTGGTAGCATCC
IFNg CTGAGACAATGAACGCTACAC TTTCTTCCACATCTATGCCAC
Bax TGCTACAGGGTTTCATCCAG ATTGCTGTCCAGTTCATCTC
BclII GATCTCTGGTTGGGATTCCT ACAACTTGCAATGAATCGGG
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small intestinal crypts by counting Ki-671 epithelial cells. At
12 h, proliferative activity was significantly higher in p31-43-
than in PBS-treated mice (Fig. 2A).
Intraluminal p31-43 increases mRNA expression of inflam-
matory cytokines. We next explored the expression of proin-
flammatory mediators induced by p31-43. Compared with
PBS-treated mice, there was a rapid and marked increase in
IFN-g mRNA 2 h after p31-43 treatment, followed by in-
creases in CXCL10 and IFN-b mRNA, which peaked 6 h after
intraluminal administration of p31-43 (Fig. 2B). The expres-
sion of mRNA for IL-15, IL-18, IL-1b, IL-6, TNF-a, and
chemokines such as MCP1, CXCR3, and CXCL2 was similar
in all groups (data not shown).
Intraluminal p31-43 induces cell death in the mucosa. Cell
death by gluten-specific and -nonspecific cytotoxic mecha-
nisms plays a role in intestinal damage in CD (31). To study
whether p31-43 has cytotoxic activity, we examined TUNEL
staining of small intestinal sections 12 h after treatment. This
revealed a large increase in the number of TUNEL-positive
cells in the lamina propria compared with PBS-treated mice
(Fig. 3A). TUNEL-positive cells were also found in the epi-
thelium of p31-43-treated but not in PBS-treated mice (white
arrows, Fig. 3A). Automated counting confirmed an increase in
the frequency of total TUNEL-positive cells, when both the
lamina propria and epithelium of p31-43-treated mice were
analyzed (Fig. 3B). The expression of anti- and proapoptotic
mediators, Bcl2 and Bax, respectively, was evaluated by qPCR
analysis of whole small intestinal mucosa. At 12 h, we found
increased Bax/Bcl2 ratio in p31-43-treated mice compared
with PBS-treated controls (Fig. 3C), suggesting that p31-43 has
a proapoptotic effect in the small intestine in vivo. Mice treated
with p31-43 had increased numbers of TUNEL-positive cells
in epithelium compared with PBS-treated control mice (Fig.
3D). A similar trend was seen in lamina propria alone although
this did not attain statistical significance. To further explore the
hypothesis that p31-43 caused death of epithelial cells, we first
Fig. 1. Intraluminal p31-43 peptide induces
pathological changes in the murine small
intestine. Representative hematoxylin and
eosin (H and E)-stained sections of proximal
small intestine of C57BL/6 mice after 12 and
72 h of intraluminal administration of p31-
43, nonrelated peptide (NRP), or PBS. Black
scale bar 5 100 mm. Red arrows show
edema, and light blue arrows show some
intraepithelial lymphocytes (IELs) (A). Mor-
phological analysis of small intestine from
C57BL/6 mice includes villus-to-crypt (V/C)
ratio, number of IELs, and histological score
after 12 h (B) and 72 h (C) (n 5 4 mice per
group, unpaired t-test, *P , 0.05, **P ,
0.01, ***P , 0.001).
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used qPCR analysis of isolated epithelial cells, which showed
a trend toward an increase in the Bax/Bcl2 ratio in intraepi-
thelial cells (IEC) from p31-43-treated mice. Although this
difference did not reach statistical significance (Fig. 3E), flow
cytometry showed an increased number of annexin V-positive/
propidium iodide-positive IECs from mice treated with p31-43
(Fig. 3F).
Mucosal changes induced by p31-43 are MyD88 and type I
IFN dependent but not Toll-like receptor 4 dependent. To
investigate possible signaling pathways that might mediate the
effects of p31-43, we used MyD88 KO, IFNaR KO, and
Toll-like receptor 4 (TLR4)-deficient (C3H-HeJ) mice. No
histological changes were observed in MyD88 KO mice 12 h
after administration of p31-43 (Fig. 4A). There were no differ-
ences in V/C ratio, IEL counts, global histological scores (Fig.
4B), or in cell death analysis (Fig. 4C) between p31-43- and
PBS-treated mice. However, TLR4-deficient C3H-HeJ mice
had decreased V/C ratios, increased IELs counts, and in-
creased global histological scores after administration of
p31-43 (Fig. 4D). The effects of p31-43 were absent in
IFNaR KO (Fig. 4E).
p31-43 and poly I:C cause mucosal damage via independent
mechanisms. Intraluminal administration of poly I:C, a syn-
thetic analog of dsRNA that mimics the innate response to viral
infection acting via TLR3 receptor, induces mucosal damage
(3). We therefore investigated the effect of intraluminal admin-
istration of p31-43 and poly I:C on mucosal damage. On the
basis of previous work that determined an optimal time point
for the induction of intestinal damage and inflammation with
poly I:C and reduced effect of surgery at 72 h (3), we used this
time point to evaluate the combined effect of p31-43 and poly
I:C. As expected, p31-43-treated mice had reduced V/C ratios
compared with control mice at 72 h (Figs. 1C and 5A), but poly
I:C alone or the combination of p31-43 1 poly I:C had a more
pronounced decrease in V/C ratios (Fig. 5A).
p31-43 and poly I:C induce distinct patterns of inflammatory
mediators. The analysis of mRNA at different time points after
treatment showed distinct patterns of expression for the proin-
flammatory cytokines IFN-b, IFN-g, and TNF-a in p31-43-,
poly I:C-, or p31-43 1 poly I:C-treated mice. Increased ex-
pression of IFN-b in the mucosa was found 2 h after treatment
with poly I:C, whereas this increase was only noted 4 h after
p31-43 1 poly I:C treatment. Induction of IFN-b was modest
and delayed until 6 h after treatment with p31-43 alone. TNF-a
expression was increased by poly I:C or p31-43 1 poly I:C but
not by p31-43 treatment. Consistent with previous results,
p31-43 induced IFN-g expression, which was not observed in
p31-43 1 poly I:C-treated or poly I:C-treated mice. Poly I:C is
a strong inducer of CXCL10 (8), which was also upregulated
by p31-43 1 poly I:C treatment, whereas CXCL10 induction
by p31-43 was weaker and delayed. A synergistic effect of
p31-43 1 poly I:C was only observed for CXCL2 and MCP1
(Fig. 5B). Altogether, these results suggest that mucosal dam-
Fig. 2. Intraluminal p31-43 peptide produces hyperproliferation in crypts and a proinflammatory response in small intestine. Evaluation of the proliferative
activity in small intestinal crypts by Ki-67-positive cell counts is shown. After 12 h posttreatment with p31-43 or PBS, samples of small intestine were stained
with anti-Ki67 antibody. Images were obtained and analyzed in a TCS SP5 confocal microscope. The plots show the number of Ki-67-positive cells per crypt
(n5 4 mice per group, unpaired t-test, **P, 0.01) (A). Real-time PCR analysis of small intestinal samples from C57BL/6 mice after intraluminal administration
of p31-43 or PBS was performed. Plots show mRNA expression after 2–12 h of p31-43 (•) or PBS (Œ) treatment. IFN-g, IFN-b, and CXCL10 mRNA expression
was assessed. All values were normalized with the housekeeping mRNA expression (HPRT). Results were expressed as fold increase of every treatment vs. the
mean of PBS treatment in every time point (22DDCt method) (n 5 4 mice per group, unpaired t-test, *P , 0.05, **P , 0.01, p31-43-treated mice vs. PBS control
in the same time point).
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age caused by p31-43 and poly I:C may employ different
pathways, which can interact in a complex fashion.
Poly I:C enhances cell death induced by p31-43. Treatment
with p31-43 led to increased cell death in the intestinal mucosa
as assessed by TUNEL staining (Fig. 3), and this was further
increased in mice given p31-43 1 poly I:C together. However,
poly I:C alone had no effect on cell death (Fig. 6A). Confirming
our previous findings, p31-43 alone also induced a proapop-
totic pattern of Bax/Bcl2 ratio 12 h after treatment, but this was
not seen in mice receiving poly I:C alone or in combination
with p31-43 (Fig. 6B). On the other hand, treatment with
p31-43 1 poly I:C induced a marked increase in the number of
cleaved-caspase 3-positive cells in lamina propria compared
with mice treated with PBS, poly I:C, or p31-43 alone (Fig.
6C). As caspase 3 is central to both the intrinsic and extrinsic
pathways of apoptosis, these results suggest that p31-43 1
poly I:C is a stronger stimulus for cell death than poly I:C or
p31-43 alone and that the pathways involved may be different.
DISCUSSION
In this study, we found that intraluminal administration of
p31-43 reduced V/C ratio, increased IEL infiltration, and led to
higher histological scores in wild-type (C57BL/6) mice.
p31-43 caused an inflammatory response in the small intestine,
characterized by elevation of IFN-g expression followed by
elevations in IFN-b and CXCL10. p31-43 also induced cell
death in epithelial cells. Treatment with p31-43 in mice lacking
TLR4 induced similar morphological changes than in wild-
type but not in mice lacking the MyD88 molecule. The results
indicate a direct proinflammatory effect of p31-43 in vivo that
requires the central adaptor of the TLR pathway, MyD88, but
is independent of TLR4. Finally, we demonstrated that the
mucosal damage induced by p31-43 is type I IFN dependent.
There is controversy on the potential induction of the innate
immune response by gliadin peptides. Critiques are based on
the lack of specific receptor identification and reports on in
vivo effects. p31-43 has been shown to trigger inflammation
using cell lines and duodenal biopsies, whereas instillation of
p31-49 into the duodenum of treated patients with CD led to
reduced V/C ratios and increased IEL counts within 4 h after
administration (4, 33). Others have shown that chemokines
IP-10 (CXCL10) and MCP-5, which recruit monocytes and T
cells, were increased in vitro by p31-43 (34), as well as cell
proliferation and proapoptotic activity (4, 6, 12). In this study,
we provide evidence for in vivo innate immune stimulation and
apoptosis by p31-43. We found that intraluminal p31-43 stim-
ulated a broad spectrum of proinflammatory genes such as
IFNg, CXCL10, and IFNb, increased the number of Ki-67-
positive cells in crypts of C57BL/6 mice, and increased cellular
death in lamina propria and in epithelial cells. A high number
of TUNEL-positive cells was found in p31-43-treated mice,
which was associated with a proapoptotic profile (high Bax/
Fig. 3. Intraluminal p31-43 induces cell death in
the small intestinal mucosa. Sections of small
intestine after 12 h posttreatment with p31-43 or
PBS were stained with TUNEL reaction. Sections
were analyzed by confocal microscopy. Images
were taken from a confocal microscope Olympus
FV1000. White arrows point to some TUNEL-
positive nuclei in the epithelial layer. Scale bar 5
100 mm (A). TUNEL-positive/total cells from
mucosa were determined using ImageJ software
(B). The expression of anti- and proapoptotic
mediators, Bcl2 and Bax, respectively, was eval-
uated by quantitative PCR analysis of small in-
testinal mucosa; results were plotted as Bax/Bcl2
ratio (C). TUNEL-positive/total cells from epi-
thelium (Ep) and lamina propria (LP), separately,
were determined using ImageJ software (D). Ep-
ithelial cells were isolated from small intestine 12
h after treatment with p31-43 or PBS, and the
expression of Bcl2 and Bax was evaluated by
quantitative PCR; results were plotted as Bax/
Bcl2 ratio (E). Isolated epithelial cells were
stained with annexin V and propidium iodide and
analyzed by flow cytometry (F) (n 5 4 mice per
group, unpaired t-test, *P , 0.05, **P , 0.01,
p31-43-treated mice vs. PBS control).
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Bcl2 ratio). Finally, cell death evaluated by qPCR (Bax/Bcl2
ratio), fluorescence microcopy (TUNEL reaction), and flow
cytometry (annexin V/propidium iodide) indicated that p31-43
may induce enterocyte death in vivo.
Some previous studies demonstrated that PT-gliadin induced
proinflammatory genes in a MyD88-dependent manner but a
TLR2- and TLR4-independent manner (34), whereas others
showed that gliadin-derived peptides increased inflammatory
mediators through TLR4/MyD88/TRIF/MAPK/NFkB and
NLRP3 inflammasome pathways (25). Although these findings
suggest that innate response via TLR signaling and inflam-
masome can be elicited by gliadin peptides, p31-43 was not
specifically evaluated. Type I IFNs play a critical role in our
experimental model, as p31-43 induced the expression of type
I IFNs in vivo, and its effects on intestinal pathology were
absent in IFNaR KO mice. Type I IFNs have been suggested
as early mediators of CD pathogenesis, and MxA, a down-
stream element of the type I IFN pathway, has been reported to
be increased in duodenal biopsies of untreated patients with
CD (13). Although it is not known what factors might drive the
induction of type I IFNs in patients at risk of CD, viral
infection is an obvious potential candidate (15, 31, 32). A role
for type I IFNs might also overlap with the proposed involve-
ment of IL-15 in CD (15), as, although these mediators activate
different downstream pathways, IL-15 upregulation during
experimental virus infection depends on IFNaR signaling (11).
Our data suggest that p31-43 and viral infection could act in
synergy to induce the innate immune responses such as IL-15
production thought to be critical for the initiation of tissue
pathology in CD. To test whether pathways induced by p31-43
and other stimuli synergize to worsen the innate immune
response, we employed a poly I:C model (3). We observed
distinct proinflammatory patterns in mice with p31-43, poly
I:C, or p31-43 1 poly I:C treatment. Poly I:C alone increased
IFN-b, TNF-a, and CXCL10. p31-43 alone induced IFN-b and
CXCL10 at lower levels, and it was the only stimulus that
rapidly increased IFN-g. The combination of p31-43 and poly
I:C increased IFN-b, TNF-a, and CXCL10 and was the only
stimuli that increased CXCL2 and MCP-1. CXCL10, CXCL2,
Fig. 4. Changes induced by p31-43 are MyD88
and type I IFN dependent. Representative H and
E-stained sections of proximal small intestine
of MyD88 mice after 12 and 72 h of intralumi-
nal administration of p31-43 or PBS are shown.
Scale bar 5 100 mm (A). Morphological anal-
ysis of small intestine from MyD88 knockout
mice treated with p31-43 or PBS included
V/C ratio, number of IELs, and histological
score after 12 h (B). Small intestinal sections
after 12 h posttreatment with p31-43 or PBS
were stained with TUNEL reaction. Sections
were analyzed by confocal microscopy. Im-
ages were taken from a confocal microscope
Olympus FV1000. Scale bar 5 100 mm.
TUNEL-positive/total cells from mucosa
were determined using ImageJ software (C).
Morphological analysis of small intestine
from C3H/HeJ mice (Toll-like receptor 4-de-
ficient mice) treated with p31-43 or PBS
included V/C ratio, number of IELs, and his-
tological score after 12 h (D). Morphological
analysis of small intestine from IFNaR2/2 mice
treated with p31-43 or PBS included V/C ratio,
number of IELs, and histological score, after 12 h
(n 5 4 mice per group, unpaired t-test, **P ,
0.01, ***P , 0.001).
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and MCP-1 are relevant for the recruitment of T cells, poly-
morphonuclear cells, and monocytes.
Analysis by TUNEL staining, Bax/Bcl2 ratio, and cleaved
caspase-3 suggests that a proapoptotic pathway is involved in
the increased cell death observed in p31-43-treated mice. In
contrast, poly I:C treatment did not induce a significant in-
crease in any of these parameters, perhaps indicating that the
histological damage caused by these stimuli may be driven by
different pathways. As well as cell apoptosis, mechanisms such
as metalloprotease- and TGF-b-induced fibrosis can all con-
tribute to tissue pathology, and these may be induced differ-
entially by individual triggers. Further support for complexity
in the pathogenic processes could come from our finding that,
in p31-43 1 poly I:C-treated mice, the number of TUNEL-
positive cells and of cleaved caspase-3-positive cells was
increased, but there was no change in Bax/Bcl2 ratio. Because
caspase-3 can be activated by both intrinsic and extrinsic
apoptotic pathways, but also can be cleaved by Granzyme B
(10), this may explain why in p31-43 1 poly I:C-treated mice
cleaved caspase-3-positive and TUNEL-positive cells were
increased but not the proapoptotic ratio. Together, our results
suggest that distinct or partially overlapping pathways of tissue
damage may be induced by p31-43 and poly I:C.
The adaptive immune response in CD is necessary for the
development of the disease; however, it is now clear that it is
insufficient to cause full intestinal pathology (21). Cytotoxic
Fig. 5. p31-43 and polyinosinic:polycytidylic acid (poly I:C) cause mucosal damage via independent mechanisms. Morphological analysis of small intestine from
C57BL/6 mice after p31-43, poly I:C (PIC), p31-43 1 PIC, or PBS treatment is shown. V/C ratio was determined after 72 h (n 5 4 mice per group, unpaired
t-test, *P , 0.05, ***P , 0.01, all treatment vs. PBS control in the same time point) (A). Real-time PCR analysis of small intestinal samples from C57BL/6
mice after p31-43, PIC, p31-43 1 PIC, or PBS administration is shown. Plots show mRNA expression after 2–12 h of p31-43, PIC, p31-43 1 PIC, or PBS
treatment. IFN-g, IFN-b, TNF-a, CXCL10, CXCL2, and MCP1 mRNA expression was assessed. All values were normalized with the housekeeping mRNA
expression (HPRT). Results were expressed as fold increase of every treatment vs. the mean of PBS treatment in every time point (22DDCt method) (n 5 4 mice per
group, 1-way ANOVA, ●P , 0.05 and ●●P , 0.01 p31-43 1 poly I:C vs. poly I:C; *P , 0.05, ***P , 0.001 p31-43 1 poly I:C vs. PBS; #P , 0.05, ##P , 0.01,
###P , 0.001 p31-43 1 poly I:C vs. p31-43, in the same time point).
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activity of IELs has been considered as a key element for
enterocyte damage. Although increased number and activation
of IELs are a hallmark of CD, how these cells are induced and
activated is still a matter of discussion. Setty et al. (30) have
recently suggested that epithelial stress and antigluten adaptive
immune responses can be independently induced at early
stages of the disease. In accordance with these results, previous
reports from our group revealed the presence of epithelial
stress in active CD (2). Altogether, the results raise the hy-
pothesis that, by activating innate immunity, peptides such as
p31-43 may lead to epithelial stress, a condition that together
with the adaptive immune response would facilitate the devel-
opment of enteropathy in CD. It remains to be determined
whether this mechanisms could also have implications for
other gluten-related disorders such as non-celiac gluten sensi-
tivity (29). Our work shows that induction of inflammation by
nonimmunogenic peptides depends on MyD88, but not TLR4,
signaling. In contrast, wheat amylase-trypsin inhibitors have
been identified as potent stimulators of an inflammatory reac-
tion through activation of TLR4 signaling on monocytes,
macrophages, and dendritic cells (14). Therefore, it is possible
that nonimmunogenic gluten peptides and nongluten proteins
in wheat induce inflammation through different pathways,
facilitating the onset of CD and other intestinal inflammatory
diseases.
In summary, in vivo inflammatory changes driven by p31-43
and poly I:C occur through different pathways, as judged by
the kinetics of the mucosal damage and histological recovery.
Although the receptor for p31-43 has not been identified yet,
different cells can produce inflammatory mediators after incu-
bation with this peptide. Because HLA-DQ2 or DQ8 molecules
do not present p31-43 and the mucosal changes observed are
MyD88 and type I IFN dependent, future work should deter-
mine the effect of p31-43 in other genetically modified mouse
strains. Signals triggered by gliadin-derived peptides, particu-
larly p31-43, in addition to those elicited by certain infections,
may exacerbate inflammation, promoting the development of
intestinal pathology in a genetically susceptible individual.
Fig. 6. Poly I:C enhances cell death induced
by p31-43. Sections of small intestine after
12 h posttreatment with p31-43 or PBS were
stained with TUNEL reaction. Sections were
analyzed by confocal microscopy. Images
were taken from a confocal microscope Olym-
pus FV1000. Scale bar 5 100 mm. TUNEL-
positive/total cell ratio was determined using
ImageJ software (A) (n 5 4 mice per group,
unpaired t-test, *P , 0.05, **P , 0.01, p31-
43-treated mice vs. PBS control). The expression
of anti- and proapoptotic mediators, Bcl2 and
Bax, respectively, was evaluated by quantitative
PCR analysis of small intestinal mucosa; results
were plotted as Bax/Bcl2 ratio (n 5 4 mice per
group, unpaired t-test, *P , 0.05, **P , 0.01,
p31-43-treated mice vs. PBS control) (B). Ex-
pression of cleaved caspase-3 was assessed by
confocal microscopy. Anti-cleaved caspase-3
antibody conjugated to FITC was used. Nuclei
were stained with propidium iodide. Images
were obtained and analyzed in a TCS SP5 con-
focal microscope combined with Leica LAS AF
software. Scale bar 5 100 mm (C).
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